CD4 News and Research

RSS

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

IL-2 compound ineffective against HIV-AIDS

An international research team has demonstrated that treating HIV-AIDS with interleukin-2 (IL-2) is ineffective. As a result, the researchers recommend that clinical trials on this compound be stopped.

19 Oct 2009

Mothers receiving HAART less likely to transmit HIV virus to their newborns through breastfeeding

Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding, according to a new study.

19 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Premature aging of immune system develops amyotrophic lateral sclerosis

Premature aging of the immune system appears to play a role in the development of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to research scientists from the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center, the Weizmann Institute of Science in Israel, and Sheba Medical Center in Israel.

9 Oct 2009

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

A new study from the Trudeau Institute in Saranac Lake, New York, demonstrates that immune system cells important for both pathogen resistance and vaccine efficacy live longer in older animals but because of this longevity acquire functional defects. The work may provide new targets for boosting immune system function in older individuals.

6 Oct 2009

Professor's research to transform mobile phones into powerful medical devices

Cell phones have come a long way in the last decade. Today, one can talk, text message, shoot photos and video, send and receive e-mail, and even access the Web. Now imagine a cell phone that can be used to monitor diseases like HIV or malaria and to test water quality after a major disaster like a hurricane or earthquake.

3 Oct 2009

HIV/Aids five times more prevalent in American prisons than in general population: Study

HIV/Aids is up to five times more prevalent in American prisons than in the general population. Adherence to treatment programs can be strictly monitored in prison. However, once prisoners are released, medical monitoring becomes problematic.

1 Oct 2009

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s.

25 Sep 2009

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania.

23 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Importance of residual thymopoiesis in aged adults

Doctor Manuel Leal is managing the Experimental Immune Virology Laboratory (in Virgen del Rocío University Hospital and Instituto de Biomedicina de Sevilla (IBIS), where clinic and basic science researchers work) where he leads a project to establish the functional nature of the thymus gland in adults. So far, it has been proven that this gland keeps on producing lymphocytes in the old age (Ferrando-Martínez et al. AGE, in press), which is a novelty because until very recently it was considered that this organ lost its immune capacity after the puberty.

22 Sep 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

Funding, health professional shortage could prevent South Africa from reaching 2011 ARV target, Health Minister says

South Africa's shortage of health professionals combined with a budget shortfall of over $130 million for the government's HIV programs could keep the country from reaching its goal of providing 80 percent of the people living with HIV/AIDS in need of treatment with antiretroviral drugs (ARVs) by 2011.

17 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

FluCide more effective than Tamiflu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.

15 Sep 2009

Phase II VICTOR-E1 clinical study results reported

Schering-Plough Corporation today reported long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients.

15 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

9 Sep 2009

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009.

9 Sep 2009

CD4 News and Research

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

IL-2 compound ineffective against HIV-AIDS

Mothers receiving HAART less likely to transmit HIV virus to their newborns through breastfeeding

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Premature aging of immune system develops amyotrophic lateral sclerosis

New study to boost immune cells for pathogen resistance and vaccine efficacy in elderly

Professor's research to transform mobile phones into powerful medical devices

HIV/Aids five times more prevalent in American prisons than in general population: Study

Non-AIDS-defining malignancies more prevalent among HIV-infected patients than non-HIV patients

FDA accepts Sangamo's IND for repeat-dosing in Phase 1 clinical trial of SB-728-T ZFN-based therapeutic

Tregs to set the pace of recovery after serious lung injury

Importance of residual thymopoiesis in aged adults

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

Funding, health professional shortage could prevent South Africa from reaching 2011 ARV target, Health Minister says

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

FluCide more effective than Tamiflu

Phase II VICTOR-E1 clinical study results reported

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

INSPIRE Phase I/IIa study data to be presented at ICAAC

Teva Pharmaceutical Industries to present MS treatment research data

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News